NCT00518492已完成1 期
Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500
Wyeth is now a wholly owned subsidiary of Pfizer3 个研究点 分布在 1 个国家目标入组 73 人开始时间: 2007年8月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 73
- 试验地点
- 3
- 主要终点
- Immunogenicity at 6 and 12 months post 6108A1-500 study.
研究概览
简要总结
Upon completion of participation in the 6108A1-500 study, subjects will be asked to consent for this duration of immunity study to provide up to two additional blood samples. SBA & IgG testing will be done on these samples taken at 6 & 12 months. The sites participating in this duration of immunity study are the same sites participating in the 6108A1-500 study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 25 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Completed study 6108A1-500 (three doses administered and visit 9 completed).
排除标准
- •Bleeding diathesis or condition associated with prolonged bleeding time.
- •Any clinically significant chronic disease that, in the investigators judgment may be worsened by blood draw.
结局指标
主要结局
Immunogenicity at 6 and 12 months post 6108A1-500 study.
时间窗: 6 and 12 months
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
2 期
Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus VaccineTick Borne EncephalitisNCT00890422Elisabethinen Hospital99
进行中（未招募）
不适用
A study to find out how long a person continues to have antibodies against Meningococcal B disease following vaccinatioEUCTR2011-005697-31-DEPfizer Inc., 235 East 42nd Street, New York, NY 100171,200
进行中（未招募）
1 期
A DURATION OF IMMUNITY STUDY, TO ASSESS PERSISTENCE OF hSBA RESPONSE FOR UP TO 48 MONTHS AFTER COMPLETION OF VACCINATION WITH BIVALENT rLP2086 VACCINEMeningococcal type B Bacterial MeningitisMedDRA version: 15.0Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-005697-31-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017698
已完成
1 期
A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1Seasonal InfluenzaNCT01818362University of Oxford72
已完成
不适用
Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 VaccineCOVID-19NCT05072496Centers for Disease Control and Prevention, China150